Posted by Michael Wonder on 14 Nov 2024
Actuate announces FDA rare paediatric disease designation granted to elraglusib for treatment of Ewing sarcoma
12 November 2024 - On-going enrolment in Phase 1/2 trial of elraglusib in relapsed/refractory Ewing sarcoma with topline Phase 1 data expected in 2H, 2025.
Actuate Therapeutics announced that the US FDA has granted rare paediatric disease designation to elraglusib, a novel GSK-3β inhibitor for treatment of Ewing sarcoma.
